Evidence map›Paper›PMID 31711924›Full record

ArticleGastroenterology2020

ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.

Mingyang Liu, Yuqing Zhang, Jingxuan Yang, Xiaobo Cui, Zhijun Zhou, Hanxiang Zhan, Kai Ding, Xiang Tian, Zhibo Yang, Kar-Ming A Fung and 9 more

Open access · greenAbstract read
In one paragraph

Article in Gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 136 citations in OpenAlex.

  1. Role of ZEB1 in angiogenesis and therapeutic potential (Review).International journal of molecular medicine · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Exploring the interactions of integrins and CEACAM6 (Review).Experimental and therapeutic medicine · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Mingyang LiuDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Yuqing ZhangDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Jingxuan YangDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Xiaobo CuiDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Zhijun ZhouDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Hanxiang ZhanDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Kai DingDepartment of Biostatistics and Epidemiology, College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Xiang TianDepartment of Chemistry and Biochemistry, The University of Oklahoma, Norman, Oklahoma.
Zhibo YangDepartment of Chemistry and Biochemistry, The University of Oklahoma, Norman, Oklahoma.
Kar-Ming A FungDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Barish H EdilDepartment of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Russell G PostierDepartment of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Michael S BronzeDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Martin E Fernandez-ZapicoDepartment of Oncology, Mayo Clinic, Rochester, Minnesota; Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota.
Marc P StemmlerDepartment of Experimental Medicine 1, Nikolaus-Fiebiger-Center for Molecular Medicine, FAU University Erlangen-Nürnberg, Erlangen, Germany.
Thomas BrabletzDepartment of Experimental Medicine 1, Nikolaus-Fiebiger-Center for Molecular Medicine, FAU University Erlangen-Nürnberg, Erlangen, Germany.
Yi-Ping LiDepartment of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, Texas.
Courtney W HouchenDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Min LiDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. Electronic address: Min-Li@ouhsc.edu.
University of Oklahoma Health Sciences Center · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity of Oklahoma · USMayo Clinic · USThe University of Texas Health Science Center at Houston · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1M
Prognostic Biomarkers for ZIP4-mediated Cachexia in Pancreatic CancerR01CA203108 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI LI, MIN, LI, YI-PING · 2016 to 2020
$2.7M
ZIP4 is a Novel Molecular Target in Human Pancreatic CancerR01CA186338 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI FERNANDEZ-ZAPICO, MARTIN ERNESTO, LI, MIN · 2015 to 2019
$1.7M
From Single Cells to Tissues: a Novel Mass Spectrometry Approach for BioanalysisR01GM116116 · NIGMS · UNIVERSITY OF OKLAHOMA · PI YANG, ZHIBO · 2015 to 2019
$1.5M
NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA186338NCI NIH HHS R01 CA203108NIGMS NIH HHS R01 GM116116
6 · The paper itself

Abstract

BACKGROUND &

aimsPancreatic tumors undergo rapid growth and progression, become resistant to chemotherapy, and recur after surgery. We studied the functions of the solute carrier family 39 member 4 (SLC39A4, also called ZIP4), which regulates concentrations of intracellular zinc and is increased in pancreatic cancer cells, in cell lines and mice.

methodsWe obtained 93 pancreatic cancer specimens (tumor and adjacent nontumor tissues) from patients who underwent surgery and gemcitabine chemotherapy and analyzed them by immunohistochemistry. ZIP4 and/or ITGA3 or ITGB1 were overexpressed or knocked down with short hairpin RNAs in AsPC-1 and MIA PaCa-2 pancreatic cancer cells lines, and in pancreatic cells from KPC and KPC-ZEB1-knockout mice, and pancreatic spheroids were established; cells and spheroids were analyzed by immunoblots, reverse transcription polymerase chain reaction, and liquid chromatography tandem mass spectrometry. We studied transcriptional regulation of ZEB1, ITGA3, ITGB1, JNK, and ENT1 by ZIP4 using chromatin precipitation and luciferase reporter assays. Nude mice were given injections of genetically manipulated AsPC-1 and MIA PaCa-2 cells, and growth of xenograft tumors and metastases was measured.

resultsIn pancreatic cancer specimens from patients, increased levels of ZIP4 were associated with shorter survival times. MIA PaCa-2 cells that overexpressed ZIP4 had increased resistance to gemcitabine, 5-fluorouracil, and cisplatin, whereas AsPC-1 cells with ZIP4 knockdown had increased sensitivity to these drugs. In mice, xenograft tumors grown from AsPC-1 cells with ZIP4 knockdown were smaller and more sensitive to gemcitabine. ZIP4 overexpression significantly reduced accumulation of gemcitabine in pancreatic cancer cells, increased growth of xenograft tumors in mice, and increased expression of the integrin subunits ITGA3 and ITGB1; expression levels of ITGA3 and ITGB1 were reduced in cells with ZIP4 knockdown. Pancreatic cancer cells with ITGA3 or ITGB1 knockdown had reduced proliferation and formed smaller tumors in mice, despite overexpression of ZIP4; spheroids established from these cells had increased sensitivity to gemcitabine. We found ZIP4 to activate STAT3 to induce expression of ZEB1, which induced expression of ITGA3 and ITGB1 in KPC cells. Increased ITGA3 and ITGB1 expression and subsequent integrin α3β1 signaling, via c-Jun-N-terminal kinase (JNK), inhibited expression of the gemcitabine transporter ENT1, which reduced gemcitabine uptake by pancreatic cancer cells. ZEB1-knockdown cells had increased sensitivity to gemcitabine.

conclusionsIn studies of pancreatic cancer cell lines and mice, we found that ZIP4 increases expression of the transcription factor ZEB1, which activates expression of ITGA3 and ITGB1. The subsequent increase in integrin α3β1 signaling, via JNK, inhibits expression of the gemcitabine transporter ENT1, so that cells take up smaller amounts of the drug. Activation of this pathway might help mediate resistance of pancreatic tumors to chemotherapeutic agents.

Indexed as

AdenocarcinomaAnimalsAntimetabolites, AntineoplasticCation Transport ProteinsCell Line, TumorCell ProliferationCisplatinDeoxycytidineDrug Resistance, NeoplasmEquilibrative Nucleoside Transporter 1FluorouracilGemcitabineGene Knockdown TechniquesHumansIntegrin alpha3Integrin beta1Antimetabolites, AntineoplasticCation Transport ProteinsCisplatinDeoxycytidineEquilibrative Nucleoside Transporter 1FluorouracilGemcitabineIntegrin alpha3Integrin beta1ITGA3 protein, humanItga3 protein, mouseItgb1 protein, humanItgb1 protein, mouseJNK Mitogen-Activated Protein KinasesSLC29A1 protein, humanSLC39A4 protein, humanSTAT3 protein, humanSTAT3 Transcription FactorZEB1 protein, humanZEB1 protein, mouseZinc Finger E-box-Binding Homeobox 1EMTOncogenePancreasSignal Transduction

Identifiers

PMID31711924
PMCPMC7837454
OpenAlexW2986868963

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.